

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 July 2023 (20.07.2023)



(10) International Publication Number
WO 2023/137044 A2

(51) International Patent Classification:

C07C 213/08 (2006.01) C07C 217/20 (2006.01)
C07C 213/10 (2006.01)

(21) International Application Number:

PCT/US2023/010567

(22) International Filing Date:

11 January 2023 (11.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/298,908 12 January 2022 (12.01.2022) US
63/437,045 04 January 2023 (04.01.2023) US

(71) Applicant: **ATOSSA THERAPEUTICS, INC.** [US/US];
107 Spring Street, Seattle, Washington 98104 (US).

(72) Inventors: **SUN, Yao-Lin**; c/o KriSan Biotech Co., Ltd.,
4F No. 30, Ln. 31, Sec. 1, Huandong Rd., Xinshi Dist.,

Tainan City, 741 (TW). **LO, Wei-Jen**; c/o KriSan Biotech Co., Ltd., 4F No. 30, Ln. 31, Sec. 1, Huandong Rd., Xinshi Dist., Tainan City, 741 (TW). **HUNG, Kun-Chih**; c/o KriSan Biotech Co., Ltd., 4F No. 30, Ln. 31, Sec. 1, Huandong Rd., Xinshi Dist., Tainan City, 741 (TW). **HSU, Chia-Chen**; c/o KriSan Biotech Co., Ltd., 4F No. 30, Ln. 31, Sec. 1, Huandong Rd., Xinshi Dist., Tainan City, 741 (TW). **QUAY, Steven C.**; c/o Atossa Therapeutics, Inc., 107 Spring Street, Seattle, Washington 98104 (US).

(74) Agent: **HARWOOD, PH.D., Melissa M.** et al.; DLA PIPER LLP, 701 Fifth Avenue, Suite 6900, Seattle, Washington 98104-7029 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

(54) Title: COMPOSITIONS OF (Z)-ENDOXIFEN AND METHODS OF ENRICHMENT THEREOF




FIG. 13

(57) Abstract: Described herein are methods of making (Z)-endoxifen, a salt thereof, crystalline forms of endoxifen, and compositions comprising them. Also described herein are crystalline forms of (Z)-endoxifen. A method of making (Z)-endoxifen may include one or more enrichment steps to enrich the amount of (Z)-endoxifen present in a composition. Enrichment may include one or more steps of crystallization, recrystallization, or fractional recrystallization to reduce the level of one or more impurities in the composition. These methods may be industrially scalable. Also described herein are compositions enriched for (Z)-endoxifen produced by the methods described herein.

[Continued on next page]

WO 2023/137044 A2

LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*